Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Rhythm Pharmaceuticals, Inc. (RYTM)
Price$102.39Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | $170.3M | $116.8M | $68.1M | $21.5M | $2.6M | — | — | — | — | — | — |
| Gross margin | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% | — | — | — | — | — | — |
| Research & development | $167.3M | $238.0M | $135.0M | $108.6M | $104.1M | $90.5M | $109.5M | $50.3M | $22.9M | $19.6M | $7.1M |
| Operating expenses | $381.8M | $395.6M | $261.8M | $202.8M | $173.2M | $136.6M | $146.0M | $78.4M | $32.4M | $25.9M | $10.6M |
| Operating income | −$192.0M | −$265.5M | −$184.4M | −$179.2M | −$170.1M | −$136.6M | −$146.0M | −$78.4M | −$32.4M | −$25.9M | −$10.6M |
| Operating margin | −101.19% | −204.04% | −238.10% | −757.92% | −5,391.85% | — | — | — | — | — | — |
| EBITDA | −$191.5M | −$264.8M | −$183.5M | −$178.3M | −$169.2M | −$135.9M | −$145.2M | −$78.0M | −$32.2M | −$25.8M | — |
| EBITDA margin | −100.93% | −203.50% | −236.94% | −754.13% | −5,365.98% | — | — | — | — | — | — |
| Net income | −$196.5M | −$260.6M | −$184.7M | −$181.1M | −$69.6M | −$134.0M | −$140.7M | −$74.1M | −$33.7M | −$25.9M | −$11.1M |
| Net profit margin | −103.57% | −200.27% | −238.52% | −766.22% | −2,207.10% | — | — | — | — | — | — |
| Basic EPSper basic share | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 | -$3.04 | -$3.86 | -$2.39 | -$2.83 | -$2.85 | -$1.18 |
| Diluted EPSper diluted share | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 | -$3.04 | -$3.86 | -$2.39 | -$2.83 | -$2.85 | -$1.18 |
Owners
Reported shareholders
9.69%of listed shares
RA CAPITAL MANAGEMENT, L.P.6.67M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 9.69%6.67M shares |
BlackRock, Inc. | 8.95%6.16M shares |
BAKER BROS. ADVISORS LP | 8.14%5.6M shares |
PRIMECAP MANAGEMENT CO/CA/ | 4.60%3.17M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.56%3.14M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.37%3.01M shares |
JPMORGAN CHASE & CO | 3.85%2.65M shares |
PERCEPTIVE ADVISORS LLC | 3.76%2.59M shares |
STATE STREET CORP | 3.74%2.57M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 3.73%2.57M shares |
WESTFIELD CAPITAL MANAGEMENT CO LP | 3.21%2.21M shares |
GOLDMAN SACHS GROUP INC | 3.09%2.13M shares |
FEDERATED HERMES, INC. | 2.59%1.79M shares |
Polar Capital Holdings Plc | 2.42%1.66M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.23%1.53M shares |
Capital Research Global Investors | 2.23%1.53M shares |
CITADEL ADVISORS LLC | 1.84%1.26M shares |
Checkpoint Capital L.P. | 1.72%1.19M shares |
Siren, L.L.C. | 1.65%1.14M shares |
MORGAN STANLEY | 1.62%1.11M shares |
Percentages use 68.82M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | TETRAULT LYNN A.Director | SellCommon Stock | 37.0K | $100.32 | $3.71M | 7.0K |
| May 15, 2026Form 4 | German Christopher PaulCorporate Controller & CAO | SellCommon Stock | 4.6K | $92.21 | $428.1K | 0 |
| Mar 4, 2026Form 4 | German Christopher PaulCorporate Controller & CAO | SellCommon Stock | 5.6K | $89.56 | $502.8K | 160 |
| Feb 19, 2026Form 4 · 10b5-1 | Smith Hunter CChief Financial Officer | SellCommon Stock | 585 | $103.28 | $60.4K | 110.5K |
| Feb 19, 2026Form 4 · 10b5-1 | Smith Hunter CChief Financial Officer | SellCommon Stock | 800 | $102.10 | $81.7K | 111.1K |